RBC Capital Positive on Alnylam Pharmaceuticals (ALNY): 'HELIOS-B Hits Convincingly Across the Board, Materially Exceeding Expectations'

Alnylam Pharmaceuticals (ALNY) PT Raised to $250 at Morgan Stanley

June 24, 2024 12:28 PM EDT

Morgan Stanley analyst Andrew Galler raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $250.00 (from $164.00) while maintaining a Equalweight rating.

The analyst comments "Top-line HELIOS-B results better-than-expected, supporting sNDA filing in late 2024. We expect focus to now shift to presentation of... More

Alnylam Pharma (ALNY) out of the money July puts and January 260 calls active as share price up 38%

June 24, 2024 11:20 AM EDT

Alnylam Pharma (NASDAQ: ALNY) 30-day option implied volatility is at 42; compared to its 52-week range of 33 to 408 as share price up 38% to $229.30 after reports results from its HELIOS-B Phase 3 study of vutrisiran. July 105 puts and 110 puts, September 85 puts and January 260 calls active at $13.20.

... More

Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst

June 24, 2024 7:58 AM EDT

Alnylam Pharma (NASDAQ: ALNY) data is positive for Ionis Pharmaceuticals (NASDAQ: IONS) and Intellia Therapeutics (NASDAQ: NTLA) and negative for BridgeBio Pharma Inc. (NASDAQ: BBIO), according to analysts at BMO.... More

BMO Capital Reiterates Outperform Rating on Alnylam (ALNY), Sees Significant Upside Following Data

June 24, 2024 7:52 AM EDT

BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $234.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY). Earlier Alnylam reported positive topline results from HELIOS-B Phase 3 study of vutrisiran, achieving statistical significance on primary and all secondary endpoints in both overall and in the monotherapy... More

Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

June 24, 2024 7:28 AM EDT

Stifel analyst Paul Matteis reiterated a Buy rating and $247.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst comments "We believe topline HELIOS-B data are highly positive and support vutrisiran becoming a blockbuster in TTR-cardiomyopathy. Specifically the trial met all... More

Alnylam Pharma (ALNY) to Resume Trading at 7:30 a.m.

June 24, 2024 7:11 AM EDT

Alnylam Pharma (NASDAQ: ALNY) to Resume Trading at 7:30 a.m.

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population Achieved 28% and 33% Reduction in Composite... More

BridgeBio Pharma (BBIO) Trades Lower After Alnylam Pharma (ALNY) Reports Positive Data

June 24, 2024 7:10 AM EDT

BridgeBio Pharma (NASDAQ: BBIO) Trades Lower After Alnylam Pharma (NASDAQ: ALNY) Reports Positive Data

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy... More

Alnylam Pharma (ALNY) Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran

June 24, 2024 7:00 AM EDT

(Updated - June 24, 2024 7:27 AM EDT)

Alnylam Pharmaceuticals, Inc.... More